GSK R&D chief Hal Barron (left) and Vir CEO George Scangos
August 31, 2020 08:00 AM EDTUpdated 10:09 AM
R&D
Coronavirus

GSK, Vir bar­rel in­to a fast PhII/III for their lead Covid-19 an­ti­body, chas­ing a mov­ing tar­get with quick OK in sight

John Carroll

Editor & Founder

Now that Eli Lil­ly and Re­gen­eron have strayed off sched­ule on the de­vel­op­ment of new an­ti­bod­ies to fight Covid-19, Glax­o­SmithK­line ex­ecs and their part­ners at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times